Pde2A Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
.infobox .infobox-gene {
background-color: #f8f9fa;
border: 1px solid #ddd;
padding: 10px;
width: 300px;
font-size: 0.9em;
}
.infobox .infobox-gene .gene-symbol {
font-weight: bold;
font-size: 1.2em;
color: #2c5282;
}
.infobox .infobox-gene .gene-name {
font-style: italic;
margin-bottom: 10px;
}
.infobox .infobox-gene table {
width: 100%;
border-collapse: collapse;
}
.infobox .infobox-gene td {
padding: 4px;
vertical-align: top;
}
.infobox .infobox-gene td.label {
font-weight: bold;
width: 40%;
color: #555;
}
.infobox .infobox-gene td.value {
width: 60%;
}
.infobox .infobox-gene a {
color: #0066cc;
text-decoration: none;
}
.infobox .infobox-gene a:hover {
text-decoration: underline;
}
PDE2A
Phosphodiesterase 2A
| Symbol | PDE2A |
| Full Name | Phosphodiesterase 2A |
| Chromosome | 11q13.4 |
| NCBI Gene | [5139](https://www.ncbi.nlm.nih.gov/gene/5139) |
| OMIM | [602952](https://www.omim.org/entry/602952) |
| Ensembl | [ENSG00000186642](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000186642) |
| UniProt | [O76074](https://www.uniprot.org/uniprotkb/O76074/entry) |
| Associated Diseases | Alzheimer's disease, cardiac function |
PDE2A (Phosphodiesterase 2A) is a cyclic nucleotide phosphodiesterase that hydrolyzes cGMP and/or cAMP. Phosphodiesterases play crucial roles in regulating intracellular signaling pathways, neuronal function, and synaptic plasticity. Dysregulated PDE2A activity has been implicated in neurodegenerative diseases including Alzheimer's disease and Parkinson's disease [pdea2020][schroder2020].
PDE2A is a dual-specificity phosphodiesterase that hydrolyzes both cAMP and cGMP with equal efficiency. It belongs to the metal-ion dependent phosphodiesterase superfamily and contains:
- N-terminal regulatory GAF domain: Binds cGMP to allosterically regulate enzyme activity
- Catalytic domain: Hydrolyzes cyclic nucleotides
- C-terminal dimerization domain: Mediates dimer formation for proper function
PDE2A is highly expressed in brain and regulates synaptic plasticity, memory, and emotional behavior [domeklopacinska2016][epifantseva2019].
PDE2A has multiple isoforms generated by alternative splicing:
- PDE2A2: Neuronal isoform, enriched in hippocampus and cortex
- PDE2A3: Astrocytic isoform
- PDE2A4: Testis-specific isoform
High expression in:
- Hippocampus (CA1, CA3 regions)
- Cortex (layers II-VI)
- Olfactory bulb
- Basal ganglia
- Cerebellum
Within neurons, PDE2A localizes to:
- Dendritic shafts
- Synaptic spines
- Axon terminals [^ichikawa2022]
PDE2A is upregulated in Alzheimer's disease brain, particularly in:
- Hippocampal neurons
- Entorhinal cortex
- Frontal cortex
Increased PDE2A activity leads to:
- Reduced cGMP levels
- Impaired synaptic plasticity
- Memory deficits
PDE2A deficiency in mouse models of AD results in improved cognitive function, suggesting PDE2A as a therapeutic target [reyesirisarri2018][stehlin2021].
In Parkinson's disease models, PDE2A contributes to neuroinflammation through:
- cAMP dysregulation in microglia
- Enhanced pro-inflammatory cytokine release
- Reduced dopaminergic neuron survival [^zhang2023]
PDE2A is involved in tau phosphorylation through cGMP-dependent pathways. Dysregulated cGMP signaling contributes to tau pathology in tauopathies including AD [^vanmierlo2022].
PDE2A inhibitors are being developed for neurodegenerative diseases [^wang2024]:
- T-adalafil: PDE2A-selective inhibitor in preclinical testing
- BAY 60-7550: PDE2A inhibitor showing promise in AD models
- PF-04447943: Clinical candidate for AD
PDE2A inhibitors have entered clinical trials for AD (TBD), with results pending.
PDE2A genetic variants are associated with:
- Cognitive function [^bollen2017]
- Age-related cognitive decline [^sanders2021]
- Risk of AD
PDE2A regulates the second messenger signaling cascade:
flowchart TD
A["Neurotransmitters"] --> B["Adenylyl Guanylyl Cyclase"]
B --> C["cAMP / cGMP"]
C --> D["PKA / PKG"]
D --> E["CREB Phosphorylation"]
E --> F["Gene Expression"]
F --> G["Synaptic Plasticity"]
H["PDE2A"] -->|"Hydrolyzes"| C
style H fill:#fff9c4999
style A fill:#99ff99
- Alzheimer's disease: Upregulated PDE2A contributes to synaptic dysfunction
- Parkinson's disease: PDE2A-mediated neuroinflammation
- Cardiac dysfunction: PDE2A in cardiac myocytes
- Depression: PDE2A in emotional regulation
The study of Pde2A Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Key discoveries [kovacs2020][popp2019]:
- 2015: First PDE2A inhibitor enters preclinical testing
- 2018: PDE2A deficiency improves cognition in AD mouse models
- 2020: PDE2A role in neuroinflammation established
- 2024: Clinical trials initiated
¶ GAF Domain Regulation
The N-terminal GAF domain of PDE2A provides unique regulatory properties:
- Binds cGMP with high affinity (Kd ~10-100 nM)
- cGMP binding causes conformational change that increases catalytic activity
- Allows PDE2A to act as a cGMP-stimulated phosphodiesterase
- Provides crosstalk between cAMP and cGMP signaling pathways
PDE2A integrates multiple synaptic signaling pathways:
- Glutamatergic signaling: NMDA receptor activation increases cGMP, regulating PDE2A activity
- Dopaminergic signaling: D1/D5 receptor-cAMP signaling modulated by PDE2A
- Cholinergic signaling: Acetylcholine acts through muscarinic receptors affecting cAMP/cGMP balance
- Serotonergic signaling: 5-HT receptors couple to cAMP/cGMP pathways
¶ Catalytic Domain Structure
The catalytic domain of PDE2A contains:
- Two metal ion binding sites (Mg2+/Zn2+)
- Substrate binding pocket recognizing cyclic nucleotide structure
- Regulatory helix that controls substrate access
- Dimerization interface for enzyme activation
PDE2A hydrolyzes cyclic nucleotides through:
- Substrate binding to catalytic site
- Metal ion-mediated phosphodiester bond cleavage
- Product release (5'-AMP or 5'-GMP)
- Turnover regulation by cGMP allosteric site
In the hippocampus, PDE2A regulates:
- Long-term potentiation (LTP)
- Memory consolidation
- Synaptic plasticity in CA1 and CA3 regions
- Spatial learning and navigation
Cortical PDE2A influences:
- Working memory
- Executive function
- Sensory processing
- Cortico-hippocampal communication
In basal ganglia circuits:
- Motor learning and habit formation
- Reward processing
- Action selection
- Locomotor activity control
PDE2A contributes to AD through multiple mechanisms:
- Elevated PDE2A activity reduces cGMP levels
- Impairs NMDA receptor signaling
- Reduces spine density and synaptic plasticity
- Contributes to memory deficits
- cGMP-dependent kinases regulate tau phosphorylation
- PDE2A dysregulation affects tau kinase/phosphatase balance
- Contributes to neurofibrillary tangle formation
- Amyloid-beta modulates PDE2A expression
- Creates feedback loop amplifying synaptic dysfunction
- Leads to progressive cognitive decline
- Microglial PDE2A regulates inflammatory responses
- cAMP dysregulation promotes cytokine production
- Enhanced neuroinflammation accelerates dopaminergic neuron loss
- Altered striatal cAMP/cGMP balance
- Impaired cortico-striatal plasticity
- Contributes to motor symptoms
PDE2A is expressed in cerebral vasculature:
- Regulates cerebral blood flow
- Neurovascular coupling dysfunction
- Contributes to vascular cognitive impairment
| Compound |
Company |
Stage |
Target |
| T-adalafil |
Toyama |
Preclinical |
PDE2A |
| BAY 60-7550 |
Bayer |
Preclinical |
PDE2A |
| PF-04447943 |
Pfizer |
Phase I |
PDE2A |
| DS-300 |
Daiichi Sankyo |
Preclinical |
PDE2A |
Key considerations for PDE2A inhibitor trials:
- Patient selection: Early-stage AD, mild cognitive impairment
- Biomarker endpoints: CSF cGMP levels, synaptic markers
- Cognitive batteries: ADAS-Cog, MMSE, neuropsychological testing
- Imaging: Amyloid PET, tau PET, FDG-PET
PDE2A inhibitors may be combined with:
- AChE inhibitors (donepezil, rivastigmine)
- NMDA receptor antagonists (memantine)
- Anti-amyloid antibodies (lecanemab, donanemab)
- Other PDE inhibitors for enhanced effect
PDE2A polymorphisms associated with:
- Cognitive performance in elderly
- AD risk and progression
- Response to PDE2A inhibitors
Potential CSF and blood markers:
- PDE2A activity levels
- cGMP/cAMP ratios
- Synaptic proteins (SNAP-25, synaptophysin)
Current models for PDE2A research:
- PDE2A knockout mice
- PDE2A-overexpressing transgenic mice
- AD model mice with PDE2A manipulation
- PD model mice with PDE2A modulation
Understanding PDE2A structure:
- X-ray crystallography of catalytic domain
- Cryo-EM studies of full-length enzyme
- GAF domain structure determination
- Allosteric inhibitor binding sites
- Dimer interface characterization
Drug development considerations:
- Blood-brain barrier penetration
- Plasma protein binding
- Half-life and dosing frequency
- Metabolite profiling
- Drug-drug interactions
Current clinical investigation:
- Phase I trials in early AD patients
- Biomarker-based patient selection
- Cognitive endpoint expectations
- Safety profile assessment
- Combination with standard care
Future applications:
- Neuroinflammation targeting
- Motor symptom improvement
- Non-motor symptom management
- Disease modification potential
- Biomarker development
Broader therapeutic potential:
- Vascular dementia
- Lewy body dementia
- Frontotemporal dementia
- Amyotrophic lateral sclerosis
- Multiple system atrophy
¶ Safety and Side Effects
PDE2A inhibitors may affect:
- Blood pressure regulation
- Heart rate and rhythm
- Cardiac contractility
- Vascular tone
Central nervous system considerations:
- Sleep quality changes
- Mood alterations
- Headache incidence
- Seizure threshold
Important interactions:
- Other phosphodiesterase inhibitors
- Cardiovascular drugs
- CNS active medications
- Cytochrome P450 substrates
Current regulatory landscape:
- Breakthrough therapy designation potential
- Accelerated approval pathway
- Biomarker qualification process
- Real-world evidence incorporation
International considerations:
- EMA scientific advice
- PMDA consultations
- Asian market strategies
- Global trial coordination
Market considerations:
- Manufacturing costs
- Development investment recovery
- Competition analysis
- Reimbursement negotiations
Economic implications:
- Reduced caregiving burden
- Delayed institutionalization
- Quality of life improvements
- Healthcare resource utilization